The phase III candidate: Can we improve the science of selection?

被引：20
作者：
Bajorin, D [1 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2004年 / 22卷 / 02期
关键词：
D O I：
10.1200/JCO.2004.10.988
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：211 / 213
页数：3
相关论文
共 10 条
  • [1] Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy
    Bajorin, DF
    Dodd, PM
    Mazumdar, M
    Fazzari, M
    McCaffrey, JA
    Scher, HI
    Herr, H
    Higgins, G
    Boyle, MG
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (10) : 3173 - 3181
  • [2] Docetaxel and cisplatin with granulocyte colony-stimulating factor (G-CSF) versus MVAC with G-CSF in advanced urothelial carcinoma: A multicenter, randomized, phase III study from the Hellenic Cooperative Oncology Group
    Bamias, A
    Aravantinos, G
    Deliveliotis, C
    Bafaloukos, D
    Kalofonos, C
    Xiros, N
    Zervas, A
    Mitropoulos, D
    Samantas, E
    Pectasides, D
    Papakostas, P
    Gika, D
    Kourousis, C
    Koutras, A
    Papadimitriou, C
    Bamias, C
    Kosmidis, P
    Dimopoulos, MA
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (02) : 220 - 228
  • [3] Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer
    Grossman, HB
    Natale, RB
    Tangen, CM
    Speights, VO
    Vogelzang, NJ
    Trump, DL
    White, RWD
    Sarosdy, MF
    Wood, DP
    Raghavan, D
    Crawford, ED
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2003, 349 (09) : 859 - 866
  • [4] A RANDOMIZED COMPARISON OF CISPLATIN ALONE OR IN COMBINATION WITH METHOTREXATE, VINBLASTINE, AND DOXORUBICIN IN PATIENTS WITH METASTATIC UROTHELIAL CARCINOMA - A COOPERATIVE GROUP-STUDY
    LOEHRER, PJ
    EINHORN, LH
    ELSON, PJ
    CRAWFORD, ED
    KUEBLER, P
    TANNOCK, I
    RAGHAVAN, D
    STUARTHARRIS, R
    SAROSDY, MF
    LOWE, BA
    BLUMENSTEIN, B
    TRUMP, D
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1992, 10 (07) : 1066 - 1073
  • [5] A PROSPECTIVE RANDOMIZED TRIAL COMPARING MVAC AND CISCA CHEMOTHERAPY FOR PATIENTS WITH METASTATIC UROTHELIAL TUMORS
    LOGOTHETIS, CJ
    DEXEUS, FH
    FINN, L
    SELLA, A
    AMATO, RJ
    AYALA, AG
    KILBOURN, RG
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1990, 8 (06) : 1050 - 1055
  • [6] Mead GM, 1997, J CLIN ONCOL, V15, P594
  • [7] Phase III trial of fluorouracil, interferon alfa-2b, and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in metastatic or unresectable urothelial cancer
    Siefker-Radtke, AO
    Millikan, RE
    Tu, SM
    Moore, DF
    Smith, TL
    Williams, D
    Logothetis, CJ
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (05) : 1361 - 1367
  • [8] Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy amd recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors:: European organization for research and treatment of cancer protocol no. 30924
    Sternberg, CN
    de Mulder, PHM
    Schornagel, JH
    Théodore, C
    Fossa, SD
    van Oosterom, AT
    Witjes, F
    Spina, M
    van Groeningen, CJ
    de Balincourt, C
    Collette, L
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (10) : 2638 - 2646
  • [9] Estimating survival benefit in castrate metastatic prostate cancer: Decision making in proceeding to a definitive phase III trial
    Verbel, DA
    Kelly, WK
    Smaletz, O
    Regan, K
    Curley, T
    Heller, G
    Scher, HI
    [J]. UROLOGY, 2003, 61 (01) : 142 - 144
  • [10] Gemcitabine and cisplatin versus methotrexate vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: Results of a large randomized, multinational, multicenter, phase III study
    von der Maase, H
    Hansen, SW
    Roberts, JT
    Dogliotti, L
    Oliver, T
    Moore, MJ
    Bodrogi, I
    Albers, P
    Knuth, A
    Lippert, CM
    Kerbrat, P
    Rovira, PS
    Wersall, P
    Cleall, SP
    Roychowdhury, DF
    Tomlin, I
    Visseren-Grul, CM
    Conte, PF
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (17) : 3068 - 3077
1